Cutia Therapeutics
HKSE 2487.HK
Cutia Therapeutics EPS (Diluted) for the year ending December 31, 2023: USD -1.35
Cutia Therapeutics EPS (Diluted) is USD -1.35 for the year ending December 31, 2023, a -34.45% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
-
Cutia Therapeutics EPS (Diluted) for the year ending December 31, 2022 was USD -1.01, a -60.15% change year over year.
-
Cutia Therapeutics EPS (Diluted) for the year ending December 31, 2021 was USD -0.63.
Key data
| Date | EPS (Diluted) | Shares (Diluted, Weighted) | Shares (Basic, Weighted) | Revenue |
|---|
Market news
Loading...
Don’t Miss A Beat
HKSE: 2487.HK
| CEO | Ms. Lele Zhang |
| IPO Date | June 12, 2023 |
| Location | China |
| Headquarters | Huanzhi Building |
| Employees | 360 |
| Sector | Consumers Staples |
| Industries | |
Description
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
Key trends
Past 5 years
StockViz Staff
February 3, 2025
Any question? Send us an email